CE
Therapeutic Areas
IN8bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INB-400 | Newly Diagnosed Glioblastoma (GBM) | Phase 2 |
| INB-200 | Newly Diagnosed Glioblastoma (GBM) | Phase 1 |
| INB-100 | Leukemia (post-Hematopoietic Stem Cell Transplant) | Phase 1 |
| INB-300 / INB-330 | Acute Myeloid Leukemia (AML) & other cancers | Preclinical |
| INB-500 | Undisclosed Cancers | Preclinical |
Leadership Team at IN8bio
WH
William Ho
Chief Executive Officer and Co-Founder
KR
Kate Rochlin, Ph.D.
President and Chief Operating Officer
LL
Lawrence Lamb, Ph.D.
Executive Vice President, Chief Scientific Officer, and Co-Founder
PM
Patrick McCall
Chief Financial Officer
SB
Stacey Bilinski
Vice President, Clinical Operations
JR
Jeremy R. Graff, Ph.D.
Interim Chairman of the Board
PB
Peter Brandt
Director
EF
Emily Fairbairn
Director
LG
Luba Greenwood
Director